{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.5","upperLimit":"82","value":"64"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Assessed by the ECOG-ACRIN data manager based upon local review of images and data sent by the local sites.\n\nTreatment response was determined by calculating the sum of the maximal cross section in 2 separate axes using enhancing lesion(s) on CT or MRI imaging. The same imaging modality was to be used throughout assessment. Complete response was defined as the disappearance of all contrast enhancing tumor size on CT or MRI, patient was off all glucocorticoids, and resolution of all meningeal and vitreous involvement if present. Response must have lasted at least 4 weeks.","dispersionType":"95% Confidence Interval","groups":[{"description":"rituximab\n\ncytarabine\n\ndexamethasone\n\nleucovorin calcium\n\nmethotrexate\n\nprocarbazine hydrochloride\n\nvincristine sulfate","id":"OG000","title":"Rituximab + Standard Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Eligible, treated patients","reportingStatus":"POSTED","timeFrame":"For the primary endpoint, complete response will be based on disease status at three weeks post the end of therapy (week 17).","title":"Complete Response Rate - Locally Reviewed","type":"PRIMARY","unitOfMeasure":"percentage of participants"}